tw1025
Small moleculeexperimental
Clinical trial activity
1 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02645175)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tw1025
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02645175 | Phase 2 | Jan 1, 2016 | Baptist Health, Baylor University, Meriyana Bio Inc., Minnesota Oncology Hematology, P.A., Northwest Cancer Specialists, P.C., Sansum Clinic, Shenandoah Oncology, P.C., Taipei Medical University, University of Kansas, US Oncology, Virginia Oncology Associates, Willamette Valley Cancer Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baptist Health | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Meriyana Bio Inc. | For profit | 1 | 1 | 1 | 2016 |
| Minnesota Oncology Hematology, P.A. | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Northwest Cancer Specialists, P.C. | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Sansum Clinic | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Shenandoah Oncology, P.C. | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Kansas | Academic/Hospital | 1 | 0 | 1 | 2016 |
| US Oncology | For profit | 1 | 0 | 1 | 2016 |
| Virginia Oncology Associates | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Willamette Valley Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2016 |
12 organizations
Page 1 / 1